SCHEMBL14799644

SCHEMBL14799644

OC1CCCc2c(Br)cncc21

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 9/20 0.50
CYP11B2 P19099 9/20 0.50
UGT2B17 O75795 2/20 0.42
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34
HTR2B P41595 1/20 0.34
MAP4K1 Q92918 1/20 0.34
ACHE P22303 1/20 0.32
BRD3 Q15059 1/20 0.32
POLB P06746 1/20 0.32
TAS1R3 Q7RTX0 1/20 0.32
TAS1R1 Q7RTX1 1/20 0.32
TAS1R2 Q8TE23 1/20 0.32
GRM5 P41594 2/20 0.31
ADRA2A P08913 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31124890 1.00 CYP11B1 (0.50) CYP11B1CYP11B2UGT2B17HTR2AHTR2C
SCHEMBL15311943 0.89 CYP11B1 (0.48) CYP11B1CYP11B2UGT2B17HTR2AHTR2C
SCHEMBL14799696 0.80 CYP11B1 (0.49) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL14799830 0.80 CYP11B1 (0.49) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL14799781 0.80 CYP11B1 (0.49) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL28058996 0.75 CYP11B1 (0.33) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL31124896 0.75 CYP11B2 (0.39) CYP11B1CYP11B2HTR2AHTR2CHTR2B
SCHEMBL17180996 0.73 KMT2A (0.44) CYP11B1CYP11B2UGT2B17ACHEBRD3
SCHEMBL13616719 0.73 KMT2A (0.44) CYP11B1CYP11B2UGT2B17ACHEBRD3
SCHEMBL13974016 0.73 KMT2A (0.44) CYP11B1CYP11B2UGT2B17ACHEBRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4696688-A1 BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-02-18 EP disclosed
CN-118852103-A CYP11B2 inhibitor compound, pharmaceutical composition and application thereof 长春金赛药业有限责任公司 2024-10-29 CN disclosed
WO-2024213042-A1 BENZO-FUSED RING COMPOUND INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海翰森生物医药科技有限公司 2024-10-17 WO disclosed
EP-2785695-B1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-06-17 EP disclosed
EP-2785695-B1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2020-06-17 EP disclosed
EP-3057941-B1 NEW PHENYL-DIHYDROPYRIDINE DERIVATIVES AS ALDOSTERONE SYNTHASE INHIBITORS HOFFMANN LA ROCHE (CH) 2019-11-20 EP disclosed
EP-2758388-B1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-02-21 EP disclosed
EP-2758388-B1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2018-02-21 EP disclosed
EP-2838883-B1 NEW PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-11-08 EP disclosed
EP-2838883-B1 NEW PHENYL-TETRAHYDROISOQUINOLINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-11-08 EP disclosed
WO-2013079452-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-06-06 WO disclosed
US-20130143863-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-06 US disclosed
US-20130143863-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-06 US disclosed
US-20130143863-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-06 US disclosed
WO-2013079452-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-06-06 WO disclosed
US-20130079365-A1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-28 US disclosed
WO-2013041591-A1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-28 WO disclosed
WO-2013041591-A1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2013-03-28 WO disclosed
US-20130079365-A1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-28 US disclosed
US-20130079365-A1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES CINCOR PHARMA, INC. 2013-03-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079365-A1 NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES REN, MC2R, C1S CYP11B1 8/4885CYP11B2 5/4885UGT2B17 905/4885
US-20130143863-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES CYP11B1, CYP11B2, HSD11B1 CYP11B1 1/4885CYP11B2 2/4885UGT2B17 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.